Therapeutic time window of flurbiprofen axetil's neuroprotective effect in a rat model of transient focal cerebral ischemia

Chinese Medical Journal

Volumn 121, Issue 24, 2008, Pages 2572-2577

  Wang, Chen ^a   Liu, Jun Le ^a   Sang, Han Fei ^a   Lu, Yan ^a   Dong, Hai Long ^a   Xiong, Li Ze ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cerebral ischemia; Flurbiprofen axetil; Neurologic deficit score; Neuroprotection; Therapeutic time window

Indexed keywords

FLURBIPROFEN AXETIL; TRIPHENYLTETRAZOLIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INFARCTION; BRAIN INFARCTION SIZE; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG DOSE COMPARISON; DRUG EFFICACY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; RAT; REPERFUSION; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

EID: 60649084047     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200812020-00019     Document Type: Article

References (26)

1. Culman J, Zhao Y, Gohlke P, Herdegen T PPAR-γ: therapeutic target for ischemic stroke. Trends Pharmacol Sci 2007; 28: 244-249.
2. Iadecola C, Alexander M. Cerebral ischemia and inflammation. Curr Opin Neurol 2001; 14: 89-94.
3. Nakayama M, Uchimura K, Zhu RL, Nagayama T, Rose ME, Stefter RA, et. al. Cyclooxygenase-2 inhibition prevents delayed death of CAl hippocampal neurons following global ischemia. Proc Natl Acad Sci U S A 1998; 95: 10954-10959.
4. Martínez-González J, Badimon L. Mechanisms underlying the cardiovascular effects of COX-inhibition: benefits and risks. Curr Pharm Des 2007; 13: 2215-2227.
5. Salzberg-Brenhouse HC, Chen EY, Emerich DF, Baldwin S, Hogeland K, Ranelli S, et al. Inhibitors of cyclooxygenase-2, but not cyclooxygenase-1 provide structural and functional protection against quinolinic acid-induced neurodegeneration. J Pharmacol Exp Ther 2003; 306: 218-228.
6. Candelario-Jalil E, Gonzalez-Falcon A, Garcia-Cabrera M, Alvarez D, Al-Dalaln S, Martinez G, et al. Assessment of the relative contribution of COX-1 and COX-2 isoforms to ischemia-induced oxidative damage and neurodegeneration following transient global cerebral ischemia. J Neurochem 2003b; 86: 545-555.
7. Zea-Longa EL, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 1989; 20: 84-91.
8. Xiong LZ, Yang J, Wang Q, La ZH. Involvement of δ- and μ-opioid receptors in the delayed cerebral ischemic tolerance induced by repeated electroacupuncture preconditioning in rats. Chin Med J 2007; 120: 394-399.
9. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998; 38: 97-120.
10. Garcia JH, Wagner S, Liu KF, Hu XJ. Incomplete infarction and delayed neuronal death after transient middle cerebral artery occlusion in rats. Stroke 1997; 28: 2303-2310.
11. Xiong L, Zheng Y, Wu M, Hou L, Zhu Z, Zhang X, et al. Preconditioning with isoflurane produces dose-dependent neuroprotection via activation of adenosine triphosphate-regulated potassium channels after focal cerebral ischemia in rats. Anesth Analg 2003; 96: 233-237.
12. Duverger D, MacKenzie E. The quantification of cerebral infarction following ischemia in the vat: influence of strain, arterial pressure, blood glucose concentration, and age. J Cereb Blood Flow Metab 1988; 8: 449-461.
13. Chen Y, Langrish CL, McKenzie B; Joyce-Shaikh B, Stumhofer JS, Mcclanahan T, et al. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J Clin Invest 2006; 116: 1317-1326.
14. Kebir H, Kreymborg K, Ifergan I, Dodelet-Devillers A, Cayrol R, Bernard M, et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 2007; 13: 1173-1175.
15. Clausen F, Lorant T, Lewén A, Hillered L. T lymphocyte trafficking: a novel target for neuroprotection in traumatic brain injury. J Neurotrauma 2007; 24: 1295-1307.
16. Choi DW. Excitotoxic cell death. J Neurobiol 1992; 23: 1261-1276.
17. Hurley SD, Olschowka JA, O'Banion MK. Cyclooxygenase inhibition as a strategy to ameliorate brain injury. J Neurotrauma 2002; 19: 1-15.
18. Kukreja RC, Kontos HA, Hess ML, Ellis EF. PGH synthase and lipoxygenase generate superoxide in the presence of NADH or NADPH. Circ Res 1986; 59: 612-619.
19. Bezzi P, Carmignoto G, Pasti L, Vesce S, Rossi D, Rizzini BL, et al. Prostaglandins stimulate calcium-dependent glutamate release in astrocytes. Nature 1998; 391:281-285.
20. Okumura T, Hayashi I, Ikezawa T, Yamanaka M, Takata T, Fujita Y, et al. Cyclooxygenase-2 inhibitors attenuate increased blood pressure in renovascular hypertensive models, but not in deoxycorticosterone-salt hypertension. Hypertens Res 2002; 25: 927-938.
21. McGeer PL, Schulzer M, McGeer EG. Arthritis and antiinflanunatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiological studies. Neurology 1996; 47: 425-432.
22. Candelario-Jalil E, González-Falcón A, García-Cabrera M, León OS, Fiebich BL. Wide therapeutic time window for nimesulide neuroprotection in a model of transient focal cerebral ischemia in the rat. Brain Res 2004; 1007: 98-108.
23. Zheng Z, Schwab S, Grau A, Berger C. Neuroprotection by early and delayed treatment of acute stroke with high dose aspirin. Brain Res 2007; 1186: 275-280.
24. Adams HP Jr, Adams RI, Brott T, Dei Zoppo, Furlan A, Goldstein LB, et al. Guidelines for the early management patients with ischemic stroke. A scientific statement from the Stroke Council of the American Stroke Association. Stroke 2003; 34: 1056-1083.
25. Bernardo A, Ajmone-Cat MA, Gasparini L, Ongini E, Minghetti L. Nuclear receptor peroxisome proliferator-activated receptor-γ is activated in rat microglial cells by the anti-inflammatory drug HCT1026, a derivative of flurbiprofen J Neurochem 2005; 92: 895-903.
26. Lenman A, Fowler CJ. Interaction of ligands for the peroxisome proliferator-activated receptor γ with the endocannabinoid system. Br J Pharmacol 2007; 151: 1343-1352.